ARQT Arcutis Biotherapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Commercial-stage biopharma specializing in differentiated topical and systemic dermatology treatments targeting immune-mediated diseases
• • New approvals: ZORYVE foam 0.3% for seborrheic dermatitis (FDA Dec 2023), scalp/body plaque psoriasis (FDA May 2025); ZORYVE cream 0.15% for atopic dermatitis (FDA July 2024); ZORYVE cream 0.05% for ages 2-5 (FDA Oct 2025)
• • Strategic shift: Terminated primary care promotion agreement with Kowa (Jan 2026), refocusing commercial efforts internally; expanded global licensing in Greater China, Southeast Asia, Japan
• • Quantitative highlight: Over 8 approvals/commercial launches of ZORYVE formulations across multiple indications from 2023 to 2026; Phase 1 study for acquired ARQ-234 expected Q1 2026
• • Noteworthy fact: Submitted sNDA for ZORYVE cream 0.3% pediatric use down to age 2 with PDUFA June 29, 2026; positive phase 2 topline data for ZORYVE cream 0.05% in infants 3 months–2 years

Risk Factors

• • Regulatory risk: oversight of cybersecurity mandated by SEC guidance on disclosure controls and procedures
• • Operational vulnerability: reliance on VP CT&S with 20 years IT experience for day-to-day cybersecurity risk management
• • Financial risk: potential material impact from cybersecurity incidents reported quarterly to Audit Committee
• • Competitive risk: exposure to evolving cyber threats requiring continuous updates to cybersecurity tools and strategies

Management Discussion & Analysis

• • Revenue $372.1M in 2025, up 123% YoY from $166.5M in 2024; ZORYVE foam up $110.4M, cream 0.15% up $58.4M, cream 0.3% up $35.9M
• • Operating expenses increased; R&D $77.1M in 2025 vs $76.4M 2024 (+1%), SG&A up by $45.2M driven by sales/marketing and compensation
• • Best segment: ZORYVE foam $181.9M in 2025 vs $71.5M 2024 (+154%); worst segment: ZORYVE cream 0.3% with smaller 42% growth
• • Cash, cash equivalents, and marketable securities at $221.3M end 2025 vs $228.6M in 2024; paid down $100M debt principal in Oct 2024
• • Management expects increased R&D and SG&A in 2026 driven by ARQ-234 clinical development and continued ZORYVE commercialization; potential funding needs from equity/debt if cash insufficient

What are the latest ARQT SEC filings in 2026?

Arcutis Biotherapeutics, Inc. (ARQT) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ARQT file its most recent 10-K annual report?

Arcutis Biotherapeutics, Inc. (ARQT) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ARQT 10-Q quarterly reports?

Arcutis Biotherapeutics, Inc. (ARQT)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every ARQT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ARQT filed recently?

Arcutis Biotherapeutics, Inc. (ARQT)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ARQT insider trading activity (Form 4)?

SignalX aggregates every ARQT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ARQT file with the SEC?

Arcutis Biotherapeutics, Inc. (ARQT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ARQT filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Arcutis Biotherapeutics, Inc. (ARQT).

What is ARQT's SEC CIK number?

Arcutis Biotherapeutics, Inc. (ARQT)'s SEC CIK (Central Index Key) number is 1787306. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1787306 to look up all ARQT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ARQT return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Arcutis Biotherapeutics, Inc. (ARQT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.